#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mitochondrial encephalomyopathy Systemic scleroderma Osteochondrodysplasia Sexually transmitted disease Mucopolysaccharidosis II Acquired ATTR amyloidosis Mantle cell lymphoma stage IV Pseudomyxoma peritonei Laryngeal squamous cell carcinoma Splenic marginal zone lymphoma Hypochromic anaemia Blastic plasmacytoid dendritic cell neoplasia Deafness Adult T-cell lymphoma/leukaemia refractory Richter's syndrome More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Trials in Disease Alagille syndrome – Life with Disease Mucopolysaccharidosis III Burkitt’s lymphoma – Basic Information Crigler-Najjar syndrome – Diagnostics Mantle cell lymphoma stage III Optic glioma – Diagnostics Angiosarcoma – Treatment Systemic mastocytosis – Life with Disease Cystic fibrosis lung – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dorzolamide Hydrochloride R3R01 Vx-522 Tigulixostat Thiamine Mocravimod Daunorubicin Hydrochloride Azd5863 Ecoo75 Tofacitinib Pehero Ethanol (96 Per Cent) Clopidogrel Hydrogen Sulfate Azd5462 Nitric Oxide Abrocitinib Disodium Levofolinate Mycophenolic Acid GOVORESTAT Ertapenem More therapies…

    Learn about Your Condition

    Low cardiac output syndrome Primary myelofibrosis Apheresis Desmoplastic melanoma Altered state of consciousness B-cell lymphoma Prolymphocytic leukaemia Indolent systemic mastocytosis Schizophreniform disorder Gaucher's disease type I Thyroidectomy Mucosal inflammation Diminished ovarian reserve Nephrogenic anaemia Hepatitis alcoholic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 positive breast cancer

  • Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Hydrocortisone Sodium Succinate
    • Tucatinib
    • Eribulin Mesylate
    Spain

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Trastuzumab
    Austria Belgium Czechia France Germany Hungary +5

  • Testing 68Ga-NOTA-ABSCINT-HER2 Imaging to Predict Treatment Response in Patients with HER2-Positive Early Breast Cancer Receiving Chemotherapy

    Recruiting

    1 1 1
    Investigated Drugs:
    • 68Ga-Nota-Abscint-Her2
    France

  • Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab Deruxtecan
    France Germany Spain

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab
    • Trastuzumab Emtansine
    • Pertuzumab
    France Germany Ireland Spain

  • Study on the Safety and Effects of Lutetium Lu-177 and ABY-271 in Patients with HER2-Positive Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • ABY-271
    • LUTETIUM LU-177
    Belgium France Germany Norway Sweden
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!